ArticleInternational urology and nephrology2004
Characteristics of end stage renal disease diabetic patients in two countries with different socioeconomic conditions.
Article in International urology and nephrology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The epidemiology of end-stage renal disease in Nigeria: the way forward.International urology and nephrology · 2011Review
- Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: review of published reports.International urology and nephrology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo identify differences that may affect morbidity and mortality of type 2 diabetic patients reaching ESRD between countries with different socioeconomic conditions.
methodsComparison of clinical and laboratory features between 21 Nigerian (N) and 57 American patients (A) reaching ESRD over a 30 month period.
resultsDifferences were noted in age at ESRD (N, 55.5+/-9.8; A, 64.5+/-9.6 years), duration of diabetes (N, 5.2+/-2.8, A: 14.9+/-4.9 years), body mass index (N, 24.5+/-4.1; A; 27.6+/-6.3 kg/m2), prevalence of left ventricular hypertrophy (N; 14%; A, 89%) and ischemic heart disease (N, 26%; A, 67%), blood pressure (N, [166.2+/-26.7]/[98.6+/-16.5] mmHg; A, [146.8+/-23.6]/[72.5+/-13.3] mmHg), creatinine clearance (N, 6.1+/-3.6; A, 14.8+/-3.5 ml/min), urine protein excretion (N, 1.2+/-0.7; A, 6.1+/-4.9 g/24-h), hematocrit (N, 28.0+/-6.0; A, 35.0+/-5.0%), serum glucose (N, 5.6+/-1.6; A, 10.5+/-5.5 mmol/l), and serum cholesterol (N, 5.32+/-2.57; A, 4.19+/-1.16 mmol/l) (all at P < or = 0.05). Differences were also found in the number of antihypertensive medications (N 1.4+/-0.6; A 2.4+/-1.2 per patient), and use of medications for diabetes (N 29%, A 79%), statins (N zero, A 61 %) and erythropoietin (N zero, A 39%). 72% of the A, but none of the N patients had a functional dialysis access prior to ESRD.
conclusionsBetween A and N patients reaching ESRD, there are differences in clinical features and laboratory values that may affect morbidity, mortality and impact on the health care resources. These differences indicate areas where further studies that could assist in the planning for ESRD care in both Nigeria and USA are required.
Indexed as
Identifiers
15787347What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.